Featured Education

Bridging the Gap to Reach Treatment Goals in DLBCL

Click here to learn more

The Evolution of HCT

Click here to learn more

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Exploring Recent Data and Treatment Strategies / Activity 1

Click here to learn more

Improving Survival in First-Line Metastatic NSCLC with Dual Checkpoint Blockade: Real-world Applications in Clinical Practice / Activity 2

Click here to learn more

Creating Patient-centered Approaches to Optimal Care: Best Practices for Utilizing BCMA-directed Therapy

Click here to learn more

Navigating the Evidence: Pathways for New and Emerging BCMA Therapies

Click here to learn more

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Demystifying the Evolving Science and Potential Role of Incretins in T2D
  • Credit: 1.25hr(s)
  • CME
  • December 7, 2023 — 
  • January 2, 2024
  • Therapeutic Areas: Diabetes, Endocrinology
  • Specialties: Diabetes, Endocrinology, Obesity
  • Location: Internet Activity Enduring
Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs. What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices?   During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. This taped satellite symposium was derived from the IDF World Diabetes Congress on December 6, 2022.
Enroll Today
View Course
  • On-Demand
Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy
  • Credit: 0.50hr(s)
  • AAPA, CME, CPE, NCPD
  • January 26, 2023 — 
  • February 8, 2024
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Multiple Myeloma
  • Location: Internet Activity Enduring
B-cell maturation antigen (BCMA) plays a promising role as a therapeutic target. In fact, several BCMA-directed therapy modalities, including bispecific antibodies, chimeric-antigen receptor T-cell (CART), and antibody-drug conjugates, are available or in development for patients with relapsed/refractory multiple myeloma (RRMM). Even with the advances in the treatment regime, it is important for oncology teams to understand the implications of the clinical data. Tune into the 1st episode of the Med Table Talk® Advancing the Standard of Care for Relapsed/Refractory Multiple Myeloma: BCMA-directed Therapy, where our leading experts will discuss: The rationale, mechanism of action, and efficacy and safety of currently available BCMA-directed therapies Prevention and management strategies for adverse events associated with BCMA agents The unmet need for representation in clinical trials
Enroll Today
View Course
  • On-Demand
CLL-SLL/MTT Episode 2 of 3 - Moving Towards Fixed-Duration Therapy in CLL and SLL
  • Credit: 0.30hr(s)
  • AAPA, CME, CPE, NCPD
  • December 1, 2022 — 
  • December 14, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Chronic Lymphocytic Leukemia (CLL), Small lymphocytic lymphoma (SLL)
  • Location: Internet Activity Enduring
The emergence of fixed-duration therapy, which combines two or more drugs within a set timeframe, has shown promise for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). However, it leads to many clinical questions regarding establishing an optimal combinational therapy and sequence to best fit the needs of the patient. Join us for the second episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement as our experts and special guests discuss the implications of the new data in fixed-duration therapy, as well as strategies to promote inclusive clinical trial participation.
Enroll Today
View Course
  • On-Demand
GVHD-E3 | ECHO Program: Sclerotic Chronic GVHD
  • Credit: 1.0hr(s)
  • CME, NCPD
  • September 26, 2022 — 
  • September 26, 2023
  • Therapeutic Areas: Family Medicine / Primary Care, General Medicine
  • Specialties: Primary Care
  • Location: Internet Activity Enduring
The goal of the GVHD Interactive Provider Network ECHO Program is to connect GVHD specialists with community providers to share expertise, discuss cases and improve patient care.     The network is based on the ECHO Model™ (Extension for Community Healthcare Outcomes) which uses proven adult learning techniques and interactive video technology to connect community providers with specialists in collaborative sessions. The sessions, designed around case-based learning and mentorship, will help primary care and community-based practitioners gain the practical expertise required to care for GVHD patients.
Enroll Today
View Course
  • On-Demand
Episode 2 of 4 - Biomarker Testing: Shaping Personalized Medicine
  • Credit: 0.15hr(s)
  • NCPD
  • November 22, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
For non-small cell lung cancer (NSCLC), the rates of 5-year survival have improved significantly over the past 10 years with improved early detection methods and the approval of highly effective targeted therapies. With an expansion of the treatment arsenal, it is up to clinicians to decipher the latest guideline recommendations and apply evolving clinical evidence to ensure optimal treatment selection and patient education. Join us for the second episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care in which our expert faculty explore the implications of test results for prognosis and discuss methods to empower patients to engage in their care.
Enroll Today
View Course
  • On-Demand
Episode 3 of 4 - Novel Therapeutics: Changing the Treatment Landscape for NSCLC
  • Credit: 0.15hr(s)
  • NCPD
  • November 28, 2022 — 
  • November 28, 2023
  • Therapeutic Areas: Hematologic Oncology, Oncology
  • Specialties: Biomarkers, NSCLC
  • Location: Internet Activity Enduring
Targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC) with actionable genetic alterations. However, the constantly changing treatment landscape plus the rapidly evolving clinical evidence and guidelines present challenges for busy oncology nursing teams. Tune into the third episode of the 4-part educational initiative Biomarker-based Therapy for NSCLC:  Improving Collaboration, Communication, and Care to learn from about new and emerging targeted therapies for NSCLC and best practices for managing patients with acquired resistance.
Enroll Today
View Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List